Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Wuxi Biologics (Cayman) ( (HK:2269) ) is now available.
WuXi Biologics (Cayman) Inc. has scheduled a board meeting for March 24, 2026 to review and approve the group’s annual results for the financial year ended December 31, 2025. The approval and subsequent publication of these results will provide investors and other stakeholders with updated insight into the company’s financial performance and operational progress over the past year.
The board, chaired by Dr. Ge Li and comprising executive, non-executive and independent non-executive directors, will also address other matters at the meeting. The announcement signals the start of the company’s formal annual reporting cycle, a key event for market participants tracking WuXi Biologics’ growth and strategic direction in the biopharmaceutical services industry.
The most recent analyst rating on (HK:2269) stock is a Hold with a HK$39.00 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
WuXi Biologics (Cayman) Inc. is a contract research, development and manufacturing organization in the biopharmaceutical sector. The group provides biologics development and manufacturing services to global pharmaceutical and biotechnology clients, supporting the discovery, development and commercialization of biologic drugs across international markets.
Average Trading Volume: 34,829,314
Technical Sentiment Signal: Buy
Current Market Cap: HK$155.9B
See more insights into 2269 stock on TipRanks’ Stock Analysis page.